You are here

CLL

ASH successes set to lift Imbruvica in CLL

ASH successes set to lift Imbruvica in CLL

Biopharma Dive

Flag link:

ASH18: CAR-T shows up in early CLL test

ASH18: CAR-T shows up in early CLL test

Biopharma Dive

Flag link:

Roche and AbbVie Push Towards First-Line CLL Treatment

Roche and AbbVie Push Towards First-Line CLL Treatment

BioSpace

clinical trials

chronic lymphocytic leukemia

Flag link:

AbbVie’s CLL drug Venclyxto too expensive for NHS, says NICE

AbbVie’s CLL drug Venclyxto too expensive for NHS, says NICE

Pharmaforum

Rituxan/MabThera

Flag link:

Priority Review for Imbruvica-Gazyva combo to treat CLL, SLL

Priority Review for Imbruvica-Gazyva combo to treat CLL, SLL

BioCentury

priority review

Flag link:

TG stock sinks after setback to blood cancer trial

TG stock sinks after setback to blood cancer trial

Fierce Biotech

TG Therapeutics

ublituximab-umbralisib

chronic lymphocytic leukemia

Flag link:

Eagle Pharmaceuticals Receives New Patent for Bendeka Configure

Eagle Pharmaceuticals Receives New Patent for Bendeka Configure

CP Wire

Eagle Pharmaceuticals

Teva Pharmaceuticals

Flag link:

AbbVie, Roche post a big win with a blockbuster FDA OK for Venclexta/Rituxan combo for leukemia

AbbVie, Roche post a big win with a blockbuster FDA OK for Venclexta/Rituxan combo for leukemia

Endpoints

chronic lymphocytic leukemia

Flag link:

AbbVie eyes Imbruvica expansion in CLL as Gazyva pairing hits its marks

AbbVie eyes Imbruvica expansion in CLL as Gazyva pairing hits its marks

Fierce Pharma

Flag link:

At Verastem, Infinity’s Former Blood Cancer Drug Heads to FDA

At Verastem, Infinity’s Former Blood Cancer Drug Heads to FDA

Xconomy

Infinity Pharma

follicular lymphoma

small lymphocytic lymphoma

Flag link:

Novartis, feeling the heat from head-to-head rivals, pulls Arzerra outside the U.S.

Novartis, feeling the heat from head-to-head rivals, pulls Arzerra outside the U.S.

Fierce Pharma

chronic lymphocytic leukemia

Flag link:

#ASH17: Late breaker from AbbVie, Roche highlights a blockbuster breakout opportunity for Venclexta in CLL

#ASH17: Late breaker from AbbVie, Roche highlights a blockbuster breakout opportunity for Venclexta in CLL

Endpoints

chronic lymphocytic leukemia

Flag link:

FDA says yes to rapid-acting Rituxan

FDA says yes to rapid-acting Rituxan

BioPharma Dive

refractory follicular lymphoma

diffuse large B-cell lymphoma

Flag link:

TG Therapeutics shares rocket up on successful PhIII leukemia study, teeing up a shot at accelerated FDA OK

TG Therapeutics shares rocket up on successful PhIII leukemia study, teeing up a shot at accelerated FDA OK

Endpoints

TG Therapeutics

Flag link:

AbbVie’s Imbruvica Expected to Become a Leading Oncology Drug

AbbVie’s Imbruvica Expected to Become a Leading Oncology Drug

Market Realist

Flag link:

JNJ's Expensive Leukemia Drug Wins British Nod

JNJ's Expensive Leukemia Drug Wins British Nod

Investopedia

chronic lymphocytic leukemia

Flag link:

Roche, AbbVie: Venclyxto Receives Positive Opinion From Committee

Roche, AbbVie: Venclyxto Receives Positive Opinion From Committee

Yahoo/GuruFocus

chronic lymphocytic leukemia

Flag link:

AbbVie Builds Upon Robust Body of IMBRUVICA® (ibrutinib) Data with Phase 3 Longer-Term Studies in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting

AbbVie Builds Upon Robust Body of IMBRUVICA® (ibrutinib) Data with Phase 3 Longer-Term Studies in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting

Yahoo

small lymphocytic lymphoma

Flag link:

Updated survival data added to Imbruvica's label

Updated survival data added to Imbruvica's label

BioPharma Dive

Flag link:

AbbVie wins FDA approval for leukemia drug

AbbVie wins FDA approval for leukemia drug

BioPharma Dive

Flag link:

Pages